Literature DB >> 23637177

Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling.

Daniel Fleck1, Frauke van Bebber, Alessio Colombo, Chiara Galante, Benjamin M Schwenk, Linnea Rabe, Heike Hampel, Bozidar Novak, Elisabeth Kremmer, Sabina Tahirovic, Dieter Edbauer, Stefan F Lichtenthaler, Bettina Schmid, Michael Willem, Christian Haass.   

Abstract

Proteolytic shedding of cell surface proteins generates paracrine signals involved in numerous signaling pathways. Neuregulin 1 (NRG1) type III is involved in myelination of the peripheral nervous system, for which it requires proteolytic activation by proteases of the ADAM family and BACE1. These proteases are major therapeutic targets for the prevention of Alzheimer's disease because they are also involved in the proteolytic generation of the neurotoxic amyloid β-peptide. Identification and functional investigation of their physiological substrates is therefore of greatest importance in preventing unwanted side effects. Here we investigated proteolytic processing of NRG1 type III and demonstrate that the ectodomain can be cleaved by three different sheddases, namely ADAM10, ADAM17, and BACE1. Surprisingly, we not only found cleavage by ADAM10, ADAM17, and BACE1 C-terminal to the epidermal growth factor (EGF)-like domain, which is believed to play a pivotal role in signaling, but also additional cleavage sites for ADAM17 and BACE1 N-terminal to that domain. Proteolytic processing at N- and C-terminal sites of the EGF-like domain results in the secretion of this domain from NRG1 type III. The soluble EGF-like domain is functionally active and stimulates ErbB3 signaling in tissue culture assays. Moreover, the soluble EGF-like domain is capable of rescuing hypomyelination in a zebrafish mutant lacking BACE1. Our data suggest that NRG1 type III-dependent myelination is not only controlled by membrane-retained NRG1 type III, but also in a paracrine manner via proteolytic liberation of the EGF-like domain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637177      PMCID: PMC6618983          DOI: 10.1523/JNEUROSCI.3372-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  70 in total

1.  BACE1 regulates the proliferation and cellular functions of Schwann cells.

Authors:  Xiangyou Hu; Hailong Hou; Chinthasagar Bastian; Wanxia He; Shupeng Qiu; Yingying Ge; Xinhua Yin; Grahame J Kidd; Sylvain Brunet; Bruce D Trapp; Selva Baltan; Riqiang Yan
Journal:  Glia       Date:  2017-02-13       Impact factor: 7.452

Review 2.  Schwann cell myelination.

Authors:  James L Salzer
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-06-08       Impact factor: 10.005

Review 3.  A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Brati Das; Riqiang Yan
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

4.  Neuregulin1 displayed on motor axons regulates terminal Schwann cell-mediated synapse elimination at developing neuromuscular junctions.

Authors:  Young Il Lee; Yue Li; Michelle Mikesh; Ian Smith; Klaus-Armin Nave; Markus H Schwab; Wesley J Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

Review 5.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

6.  Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice.

Authors:  Xiaoyang Luo; Wanxia He; Xiangyou Hu; Riqiang Yan
Journal:  Biol Psychiatry       Date:  2013-10-05       Impact factor: 13.382

7.  Structural Similarities between Neuregulin 1-3 Isoforms Determine Their Subcellular Distribution and Signaling Mode in Central Neurons.

Authors:  Detlef Vullhorst; Tanveer Ahmad; Irina Karavanova; Carolyn Keating; Andres Buonanno
Journal:  J Neurosci       Date:  2017-04-21       Impact factor: 6.167

Review 8.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

9.  Proteolytic Processing of Neuregulin 1 Type III by Three Intramembrane-cleaving Proteases.

Authors:  Daniel Fleck; Matthias Voss; Ben Brankatschk; Camilla Giudici; Heike Hampel; Benjamin Schwenk; Dieter Edbauer; Akio Fukumori; Harald Steiner; Elisabeth Kremmer; Martina Haug-Kröper; Moritz J Rossner; Regina Fluhrer; Michael Willem; Christian Haass
Journal:  J Biol Chem       Date:  2015-11-16       Impact factor: 5.157

Review 10.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.